Author: Vima Therapeutics

Vima Therapeutics to Present New Research at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

October 1, 2026
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson’s Disease

March 11, 2026

Vima Therapeutics to Present New Research at the 2026 International Congress of Parkinson’s Disease and Movement Disorders